Uncoupling of atrial natriuretic peptide extraction and cyclic guanosine monophosphate production in the pulmonary circulation in patients with severe heart failure
- PMID: 1324959
- DOI: 10.1016/0735-1097(92)90005-8
Uncoupling of atrial natriuretic peptide extraction and cyclic guanosine monophosphate production in the pulmonary circulation in patients with severe heart failure
Abstract
Objectives: This study was designed to evaluate the role of endogenous atrial natriuretic peptide in the pulmonary circulation in patients with chronic heart failure.
Background: Plasma atrial natriuretic peptide concentrations in patients with heart failure have been reported to be higher than those in normal subjects and to increase as the severity of heart failure progresses. Although endogenous atrial natriuretic peptide is thought to improve the condition of patients with heart failure by reducing preload and afterload, recent findings have indicated that a high plasma atrial natriuretic peptide level is a prognostic predictor in patients with heart failure.
Methods: To evaluate the pathophysiologic role of endogenous atrial natriuretic peptide in the pulmonary circulation, plasma atrial natriuretic peptide and cyclic guanosine monophosphate (cGMP) levels were determined in the main pulmonary artery and pulmonary capillary wedge region in 80 patients with chronic congestive heart failure (New York Heart Association functional classes II to IV).
Results: The plasma atrial natriuretic peptide level decreased significantly from the main pulmonary artery to the pulmonary capillary wedge region, whereas the plasma cGMP level increased significantly from the main pulmonary artery to the pulmonary capillary wedge region. In patients with mild chronic heart failure (n = 50), the plasma atrial natriuretic peptide level correlated with the cGMP level in the main pulmonary artery (gamma = 0.71, p less than 0.001). The atrial natriuretic peptide extraction level, calculated as (Atrial natriuretic peptide in the main pulmonary artery--Atrial natriuretic peptide in the pulmonary capillary wedge region) x Cardiac output x (1-hematocrit/100) (ng/min), also correlated with the cyclic guanosine monophosphate production level, calculated as (cGMP in the pulmonary capillary wedge region--cGMP in the main pulmonary artery) x Cardiac output x (1-hematocrit/100) (nmol/min) (gamma = 0.78, p less than 0.001). In contrast, such correlations were not found in patients with severe chronic heart failure (n = 30). In these patients, the atrial natriuretic peptide extraction level was significantly higher but there was no significant difference in the cGMP production level between the two groups (mild and severe chronic heart failure). Therefore, the molar ratio of cGMP production to atrial natriuretic peptide extraction in the pulmonary circulation was significantly lower in patients with severe chronic heart failure (88 +/- 16 vs. 480 +/- 41, p less than 0.001).
Conclusions: These results indicate that down-regulation of atrial natriuretic peptide receptors coupled to guanylate cyclase may occur in the pulmonary vascular beds of patients with severe chronic heart failure.
Similar articles
-
Possibility of downregulation of atrial natriuretic peptide receptor coupled to guanylate cyclase in peripheral vascular beds of patients with chronic severe heart failure.Circulation. 1993 Jan;87(1):70-5. doi: 10.1161/01.cir.87.1.70. Circulation. 1993. PMID: 8093432
-
Limitations of compensation by endogenous atrial natriuretic peptide in heart failure.Jpn Circ J. 1992 May;56(5):489-93. doi: 10.1253/jcj.56.489. Jpn Circ J. 1992. PMID: 1318429
-
Discrepancy between plasma and aortic wall cyclic guanosine monophosphate in an experimental model of congestive heart failure.Cardiovasc Res. 1993 Jun;27(6):1094-100. doi: 10.1093/cvr/27.6.1094. Cardiovasc Res. 1993. PMID: 8221770
-
[Functional compartmentation of the endocrine action of cardiac natriuretic peptides].Ann Endocrinol (Paris). 2000 Feb;61(1):32-40. Ann Endocrinol (Paris). 2000. PMID: 10790590 Review. French.
-
B-type natriuretic peptide for the treatment of congestive heart failure.Curr Opin Pharmacol. 2002 Apr;2(2):142-7. doi: 10.1016/s1471-4892(02)00142-x. Curr Opin Pharmacol. 2002. PMID: 11950624 Review.
Cited by
-
Ergometric exercise testing and sensitivity of cyclic guanosine 3',5'-monophosphate (cGMP) in diagnosing asymptomatic left ventricular dysfunction.Br Heart J. 1995 Feb;73(2):145-50. doi: 10.1136/hrt.73.2.145. Br Heart J. 1995. PMID: 7696024 Free PMC article.
-
Elevated pulmonary arterial and systemic plasma aldosterone levels associate with impaired cardiac reserve capacity during exercise in left ventricular systolic heart failure patients: A pilot study.J Heart Lung Transplant. 2016 Mar;35(3):342-351. doi: 10.1016/j.healun.2015.10.019. Epub 2015 Oct 19. J Heart Lung Transplant. 2016. PMID: 26586488 Free PMC article.
-
Uncoupling of atrial natriuretic peptide and cyclic guanosine 3',5'-monophosphate production in patients with liver cirrhosis.Clin Investig. 1994 Jan;72(2):138. doi: 10.1007/BF00184592. Clin Investig. 1994. PMID: 8186661 No abstract available.
-
Endothelial actions of atrial and B-type natriuretic peptides.Br J Pharmacol. 2012 May;166(2):522-31. doi: 10.1111/j.1476-5381.2012.01827.x. Br J Pharmacol. 2012. PMID: 22220582 Free PMC article. Review.
-
Differential regulation of natriuretic peptide receptor messenger RNAs during the development of cardiac hypertrophy in the rat.J Clin Invest. 1993 Dec;92(6):2702-12. doi: 10.1172/JCI116887. J Clin Invest. 1993. PMID: 7902846 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical